NCT03727308

Brief Summary

The goal of the study is to determine whether important clinical outcomes differ among women who access a combined medical abortion regimen from a pharmacy when compared with those who access it from a facility.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,196

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2018

Typical duration for all trials

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 30, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 28, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 1, 2018

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 2, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 2, 2021

Completed
Last Updated

September 5, 2021

Status Verified

September 1, 2021

Enrollment Period

3 years

First QC Date

October 28, 2018

Last Update Submit

September 2, 2021

Conditions

Keywords

medical abortionself-use

Outcome Measures

Primary Outcomes (1)

  • Need for additional treatment to complete abortion

    The primary outcome of the study will be the need for additional treatment to complete the abortion (either aspiration or repeated misoprostol) following a woman taking the medical abortion pills.

    Final assessment at 30 days following mifepristone administration

Secondary Outcomes (1)

  • Serious complications/ morbidity

    Final assessment at 30 days following mifepristone administration

Other Outcomes (1)

  • Uptake of postabortion contraception

    30 days

Study Arms (2)

Women recruited from pharmacies

Investigators will enroll women seeking medical abortion pills without prescription from pharmacies. \- Medical abortion pills sourced from pharmacies

Behavioral: Medical abortion pills sourced from pharmacies

Women recruited from health clinics

Investigators will enroll women seeking medical abortion pills from clinics. \- Medical abortion pills sourced from health clinics

Behavioral: Medical abortion pills sourced from health clinics

Interventions

One cohort using medical abortion pills sourced from pharmacies

Women recruited from pharmacies

One cohort using medical abortion pills sourced from health clinics

Women recruited from health clinics

Eligibility Criteria

Age15 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women who are pregnant and seeking abortion in study sites.

You may qualify if:

  • Women are eligible for participation if they have purchased abortion medications (mifepristone-misoprostol) independently at a pharmacy or received them from a clinic for an unwanted pregnancy at less than 9 weeks since her last menstrual period (LMP). She must meet the following criteria:
  • Be at least 15 years of age (may vary by country)
  • Have a known LMP of less than 9 weeks
  • No contraindications to medical abortion (list)
  • Willing and able to give informed consent
  • Have a mobile phone of which they are the independent user or be willing to be followed-up in person
  • Willing to be contacted with questions about her abortion by telephone (optional in-person visit) at 3, 10-14 and 30 days following initial contact.
  • Resident of country of study.

You may not qualify if:

  • Contraindications to mifepristone-misoprostol
  • Age \<15

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Health Sciences

Phnom Penh, Cambodia

Location

Regional Institute for Population Studies

Accra, Ghana

Location

Related Publications (1)

  • Kapp N, Bawah AA, Agula C, Menzel JL, Antobam SK, Asuming PO, Eckersberger E, Pearson EE. Medical abortion in Ghana: A non-randomized, non-inferiority study of access through pharmacies compared with clinics. Contraception. 2024 Dec;140:110538. doi: 10.1016/j.contraception.2024.110538. Epub 2024 Jul 11.

Study Officials

  • Nathalie Kapp, MD, MPH

    Ipas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2018

First Posted

November 1, 2018

Study Start

May 30, 2018

Primary Completion

June 2, 2021

Study Completion

June 2, 2021

Last Updated

September 5, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations